Home Blog Page 2137

Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025

By
Advertorial Desk
-

AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations

SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of three studies at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. All three studies highlight how Lunit’s AI pathology solution, Lunit SCOPE IO®, can identify biomarkers that predict response to immune checkpoint inhibitors (ICIs), offering new potential to guide more effective and personalized cancer treatment.

Among these, the first study, selected for oral presentation, was conducted in collaboration with Chiara Cremolini, MD, PhD, Professor of Medical Oncology at the University of Pisa, Italy. Researchers applied Lunit SCOPE IO to pre-treatment H&E slides from patients with proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) enrolled in the AtezoTRIBE and AVETRIC trials. The AI quantified multiple cell types within the tumor microenvironment, generating a biomarker that stratified patients into “biomarker-high” and “biomarker-low” groups.

In the AtezoTRIBE trial, biomarker-high patients treated with atezolizumab plus FOLFOXIRI/bevacizumab showed significantly improved progression-free survival (PFS) and overall survival (OS) compared to biomarker-low patients, while no such benefit was observed in the control arm. Validation in the AVETRIC cohort confirmed improved survival outcomes for biomarker-high patients receiving ICI-based therapy, with better PFS and OS compared to biomarker-low patients. These results suggest that an AI-derived tumor microenvironment biomarker could help identify patients with pMMR mCRC who are most likely to benefit from immunotherapy combinations—an urgent unmet need in this population.

A collaborative study with Yonsei University College of Medicine, Korea, evaluated whether AI-defined immune phenotypes (IP) could predict outcomes in patients with advanced clear cell renal cell carcinoma (ccRCC) treated with either nivolumab plus ipilimumab (NIVO+IPI) or sunitinib (SUN). Using Lunit SCOPE IO, tumors were classified as inflamed or non-inflamed, based on the density and spatial distribution of tumor-infiltrating lymphocytes.

Patients with inflamed tumors treated with NIVO+IPI demonstrated significantly longer PFS, OS, and higher response rates (60.5% vs. 23.2%) compared to those with non-inflamed tumors. No such benefit was observed in the SUN arm. Findings were validated in an independent ccRCC cohort and aligned with inflamed gene expression signatures from The Cancer Genome Atlas, supporting AI-based immune phenotyping as a promising biomarker to guide treatment selection between immunotherapy combinations and targeted therapies in first-line treatment for ccRCC.

The third study, conducted in collaboration with the National Cancer Center Hospital East (NCCHE) Japan, further validated the predictive power of Lunit SCOPE IO for ICI treatment response in non-small cell lung cancer (NSCLC) patients. In this multicenter prospective study, tumors classified as inflamed showed significantly better responses and longer survival with ICI therapy compared to non-inflamed tumors, a difference not observed among patients treated with cytotoxic chemotherapy. This result strengthens the evidence supporting Lunit SCOPE IO as a predictive biomarker for immunotherapy benefit in NSCLC.

“At ESMO 2025, we are demonstrating how AI can unlock predictive biomarkers directly from routine pathology slides,” said Brandon Suh, CEO of Lunit. “These findings show the potential of Lunit SCOPE IO to help identify patients who will truly benefit from immunotherapy—whether in colorectal or kidney cancer—and to guide treatment strategies that can make cancer care more precise and effective.”

Lunit’s Featured Presentations at ESMO 2025

Visit Lunit at booth #3017 to learn more about its latest AI-powered cancer research and innovations in digital pathology.

###

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit’s FDA-cleared Lunit INSIGHT suite supports cancer screening at over 7,000 medical institutions in more than 65 countries, while Lunit SCOPE is used in research partnerships with global pharma giants focused on biomarker development and companion diagnostics. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

 

Sankaty Jet Capital Launches to Deliver Lending Solutions for the Underserved Business Aviation Market

By
Advertorial Desk
-

STAMFORD, Conn., Oct. 14, 2025 /PRNewswire/ — Sankaty Jet Capital, a new business aviation finance platform, today announced its official launch. Sankaty Jet Capital, a business aviation lending platform, was formed to provide financing solutions for counterparties across the business aviation industry.

Ford von Weise, who will serve as Chief Executive Officer (CEO) of Sankaty Jet Capital, has over 25 years of experience in the business aviation finance industry. Prior to founding Sankaty Jet Capital, Mr. von Weise was Director and Head of Aircraft Finance & Advisory Services at Citi Private Bank, where he provided business aircraft financing solutions to Citi’s individual ultra-high net worth clients and corporate clients globally. Prior to his time at Citi, Mr. von Weise served as Vice President of Business Aviation Finance for Merrill Lynch Capital and GMAC Commercial Finance.

“Sankaty Jet Capital was created to fill a long-standing gap in the business aviation finance marketplace,” said Ford von Weise, CEO of Sankaty Jet Capital. “Sankaty is focused on doing one thing exceptionally well: providing financing solutions to underserved market segments.”

About Sankaty Jet Capital: 
Sankaty Jet Capital is a business aviation lending platform focused on providing financing solutions for counterparties across the business aviation industry.

CONTACT: ford@sankatyjet.com 

India’s No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch ‘Hyundai Hope for Cancer’ to revolutionize Paediatric Cancer Care

By
Advertorial Desk
-

CHENNAI, India, Oct. 14, 2025 /PRNewswire/ — Indian Institute of Technology Madras (IIT Madras), India’s No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch ‘Hyundai Hope for Cancer’ – a pioneering initiative dedicated to transforming paediatric cancer care in India.

The plaque for ‘Hyundai Hope for Cancer’ being unveiled during the Launch Event at Delhi on 3rd Sept 2025
The plaque for ‘Hyundai Hope for Cancer’ being unveiled during the Launch Event at Delhi on 3rd Sept 2025

As part of its multi-year commitment towards this cause, HMIF has allocated a social impact investment of INR 56 Crore towards this landmark project. HMIL is the Indian arm of the South Korean automaker Hyundai Motor. This initiative aligns with Hyundai’s global ‘Hope on Wheels’ program, reinforcing its longstanding commitment to supporting children battling cancer worldwide.

At the heart of this initiative is the Hyundai Centre for Cancer Genomics, housed at IIT Madras. It will also serve as a collaborative hub for clinicians, researchers, pharmaceutical scientists, and global partners, contributing to international efforts such as the International Cancer Genome Consortium (ICGC) and WHO’s International Agency for Research on Cancer (IARC).

The Centre, launched recently, will also focus on genomic sequencing to identify genetic mutations, laying the foundation for a national paediatric cancer genome database and personalized treatment protocols. It features India’s first community-based Cancer Tissue Biobank, enabling advanced genomic research in paediatric leukaemia and lymphoma.

With a total sum of INR 56 Crore committed towards this initiative, HMIF has also established a dedicated INR 3 Crore Cancer Care Fund to ensure equitable access to treatment for economically disadvantaged patients.

The project is being headed by Prof. S. Mahalingam, Department of Biotechnology, IIT Madras.

The Centre will further:

  • Collect and sequence 1,600+ samples for research
  • Provide free treatment to 30-50 children
  • Upskill 100+ technicians in genomics
  • Deploy Mobile Medical Units to expand healthcare access in underserved regions

Sharing a Message for the launch event, Shri. Dharmendra Pradhan, Hon’ble Education Minister, Government of India said, “By building an Indian childhood cancer genomic database, strengthening early detection and screening, and expanding access for underserved communities, the programme exemplifies ‘Sabka Prayas’ in action and reaffirms our commitment to equitable, technology-enabled healthcare. I call upon researchers, clinicians, and innovators across the country to collaborate through this platform to bring hope, precision care and better survival outcomes to every child in need.”

 

India’s No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch ‘Hyundai Hope for Cancer’ to revolutionize Paediatric Cancer Care

By
Advertorial Desk
-

CHENNAI, India, Oct. 14, 2025 /PRNewswire/ — Indian Institute of Technology Madras (IIT Madras), India’s No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch ‘Hyundai Hope for Cancer’ – a pioneering initiative dedicated to transforming paediatric cancer care in India.

The plaque for ‘Hyundai Hope for Cancer’ being unveiled during the Launch Event at Delhi on 3rd Sept 2025
The plaque for ‘Hyundai Hope for Cancer’ being unveiled during the Launch Event at Delhi on 3rd Sept 2025

As part of its multi-year commitment towards this cause, HMIF has allocated a social impact investment of INR 56 Crore towards this landmark project. HMIL is the Indian arm of the South Korean automaker Hyundai Motor. This initiative aligns with Hyundai’s global ‘Hope on Wheels’ program, reinforcing its longstanding commitment to supporting children battling cancer worldwide.

At the heart of this initiative is the Hyundai Centre for Cancer Genomics, housed at IIT Madras. It will also serve as a collaborative hub for clinicians, researchers, pharmaceutical scientists, and global partners, contributing to international efforts such as the International Cancer Genome Consortium (ICGC) and WHO’s International Agency for Research on Cancer (IARC).

The Centre, launched recently, will also focus on genomic sequencing to identify genetic mutations, laying the foundation for a national paediatric cancer genome database and personalized treatment protocols. It features India’s first community-based Cancer Tissue Biobank, enabling advanced genomic research in paediatric leukaemia and lymphoma.

With a total sum of INR 56 Crore committed towards this initiative, HMIF has also established a dedicated INR 3 Crore Cancer Care Fund to ensure equitable access to treatment for economically disadvantaged patients.

The project is being headed by Prof. S. Mahalingam, Department of Biotechnology, IIT Madras.

The Centre will further:

  • Collect and sequence 1,600+ samples for research
  • Provide free treatment to 30-50 children
  • Upskill 100+ technicians in genomics
  • Deploy Mobile Medical Units to expand healthcare access in underserved regions

Sharing a Message for the launch event, Shri. Dharmendra Pradhan, Hon’ble Education Minister, Government of India said, “By building an Indian childhood cancer genomic database, strengthening early detection and screening, and expanding access for underserved communities, the programme exemplifies ‘Sabka Prayas’ in action and reaffirms our commitment to equitable, technology-enabled healthcare. I call upon researchers, clinicians, and innovators across the country to collaborate through this platform to bring hope, precision care and better survival outcomes to every child in need.”

Photo: https://laotiantimes.com/wp-content/uploads/2025/10/iit_madras_hmif-1.jpg
Logo: https://laotiantimes.com/wp-content/uploads/2025/10/iit_madras_logo-1.jpg

Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix’s Biomimetic Collagen Rated “International Leading-Edge”

By
Advertorial Desk
-

—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025

CHENGDU, China, Oct. 14, 2025 /PRNewswire/ — The 2025 Chinese Biomaterials Congress recently convened in Shaoxing, Zhejiang, bringing together a prestigious gathering of leading minds in the field. Attendees included Chinese Academy of Engineering academicians Zhang Xingdong and Wang Yingjun, Chinese Academy of Sciences academicians Chen Xuesi, Tang Peifu, and Chen Chunying, alongside renowned international experts such as U.S. National Academy of Engineering member Leonard Pinchuk, UK Royal Society and Royal Academy of Engineering Fellow Molly Stevens, Professor Ki Dong Park (Fellow of the Korean Academy of Science and Technology and President of the 2024 World Biomaterials Congress), and Professor Kunio Ishikawa, President of the Japanese Society for Biomaterials. The assembly engaged in profound discussions on the frontiers and application prospects of biomaterials.

Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025
Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025

LivingPhoenix Regenerative Technologies Development (Chengdu) Co., Ltd., recognized as the world’s first scientific innovation company exclusively dedicated to the research, development, and translation of triple-helix biomimetic collagen, was invited to the Congress. The company systematically presented its proprietary research achievements in triple-helix biomimetic collagen for the first time, garnering significant attention from attending scholars, experts, and industry representatives.

At the session on Biomimetic and Life-Like Materials, Mr. Qin Xingjiong, Founder of LivingPhoenix® and Committee Member of the Rehabilitation Biomaterials Branch of the Chinese Society for Biomaterials, delivered an academic report titled “Safety and Efficacy Evaluation of a Chemically Synthesized Triple-Helix Biomimetic Collagen and Latest Research Progress.” The report detailed research collaboratively completed by his team with Beijing Hospital, Peking University Third Hospital, the Ninth People’s Hospital of Shanghai Jiao Tong University School of Medicine, and The University of Tokyo, among other institutions. The study, with Professor Zhao Hongyi of Beijing Hospital and Professor Dong Jiying of Shanghai Ninth People’s Hospital serving as corresponding authors, featured Dr. Zhang Xinling of Beijing Hospital as the first author and Dr. Li Kexin of The University of Tokyo as a co-first author. Contributors included Lu Nan, Dr. Takafumi Takebayashi, Dr. Zhou Boyu, and Xie Hongbin. The related peer-reviewed paper was published in the SCI Q1 journal Frontiers in Bioengineering and Biotechnology in April 2025. The paper concluded that the biomimetic collagen component is safe, structurally stable, thermally stable, and demonstrates good biocompatibility and functionality in both in vitro and in vivo experiments, with significant potential for promotion and application in regenerative biomedicine.

This achievement originates from fundamental research initiated in 2001 by Professor Masao Tanihara, Doctor of Engineering from Kyoto University, Japan. Developed in collaboration with the Nara Institute of Science and Technology, Kyoto University Faculty of Medicine, Kyoto Prefectural University of Medicine, and Nagoya University Graduate School, among others, the initial technological system was formed over a decade, receiving national-level support from Japanese programs including the “Knowledge Cluster Initiative” and “University Venture Creation Project.” In 2023, Dr. Takafumi Takebayashi, holder of the first-generation technology, joined LivingPhoenix® with the relevant intellectual property. The company concurrently established a core R&D team led by Dr. Zhou Boyu of The University of Tokyo, fostering continuous iteration and innovation through collaboration with Peking University, the Chinese Academy of Sciences, Shanghai Jiao Tong University, Naval Medical University, the University of Science and Technology of China, and the Tianfu Jincheng Laboratory (Frontier Medical Center). This effort achieved technological upgrades from version 1.0 to 2.0, resulting in the grant of several invention patents and the filing of multiple PCT international patent applications.

According to an assessment by Dr. Zheng Yongli, a Patent Attorney at Chengdu Gaoyuan Intellectual Property Agency, a search and analysis of 240 global peer patents and their technical solutions confirmed that the Biomimetic Collagen Technology version 1.0 is globally pioneering and internationally leading. Its version 2.0 further enhances stability and self-assembly characteristics through the “Polymerization-Induced Self-Assembly (PISA) in water” process. Notably, it represents the world’s first visualization of collagen fibrils using 300 kV Cryo-Transmission Electron Microscopy to capture the ultrastructure of “collagen fibrils,” verifying the repeatability and consistency of self-assembled morphological features across multiple production batches, thus also possessing a “globally pioneering and internationally leading” attribute.

The product currently boasts a stable triple-helix structure and collagen fibrils, effectively addressing issues common in commercially available collagen products, such as short duration of effect and suboptimal biological functionality. It also demonstrates a cost-leading advantage in its synthesis process. Amid national policies encouraging the development of domestically pioneered, internationally leading high-end medical devices, related achievements have successfully completed registration with the NMPA’s Medical Device Master File and filing as a cosmetic ingredient. Among these, the injectable biomimetic collagen lyophilized fiber has passed the classification review as a Class III medical device. Subsequent product lines suitable for functional cosmetics, medical dressings, fillers/implants, tissue engineering, and other application scenarios are slated for gradual release.

For collaboration opportunities in cosmetics, medical aesthetics, or high-end biomaterials, contact:
Email：POGMENT@mylivingphoenix.com
Official website：www.mylivingphoenix.com

TOYO’s Houston Solar Module Facility Commences Commercial Operations with Secured Customer Demands

By
Advertorial Desk
-

TOKYO, Oct. 14, 2025 /PRNewswire/ — TOYO Co., Ltd (Nasdaq: TOYO) (OTC: TOYWF),  (“TOYO” or the “Company”), a solar solution company, today announced that its new solar module manufacturing facility in the Houston metropolitan area (the “Houston Facility”) has received its Certificate of Occupancy issued by the City of Houston on 13 October 2025. This milestone marks TOYO’s commencement of full commercial operations at the Houston Facility, reinforcing TOYO’s commitment to expanding its U.S.-based manufacturing footprint.

The Houston Facility is designed to produce up to 1 GW of high-efficiency solar modules annually. During the trial production phase, the Company has received strong demand from its U.S. clients for the modules manufactured at the Houston Facility. As operations scale, TOYO anticipates robust demand from utility-scale developers seeking reliable and domestically manufactured modules that qualify for favorable tax incentives.

“This certification is a major step forward in our ‘made-in-USA-for-the-USA‘ strategy,” said Junsei Ryu, Chairman and CEO of TOYO. “We’re proud to bring high-quality solar module production to Texas and to support our partners with dependable U.S.-based supply. The strong momentum in customer orders reflects our partners’ trust in TOYO’s technology, execution and long-term commitment to the U.S. market.”

The Houston Facility is expected to qualify for tax incentives under Section 45X of the Internal Revenue Code, providing up to $0.07 per watt in production credits through 2030. This strengthens TOYO’s cost competitiveness while supporting broader goals for domestic energy manufacturing.

About TOYO Co., Ltd.

TOYO is a solar solutions company committed to becoming a full-service solar solutions provider in the global market, integrating upstream production of wafers and silicon, midstream production of solar cells, downstream production of photovoltaic modules, and potentially other stages of the solar power supply chain. TOYO is well-positioned to produce high-quality solar cells at a competitive scale and cost.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the expected growth of TOYO, the expected order delivery of TOYO, TOYO’s construction plan of manufactures, and strategies of building up an integrated value chain in the U.S. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of TOYO’s management and are not predictions of actual performance.

These statements involve risks, uncertainties, and other factors that may cause actual results, activity levels, performance, or achievements to materially differ from those expressed or implied by these forward-looking statements. Although TOYO believes that it has a reasonable basis for each forward-looking statement contained in this press release, TOYO cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the documents filed by TOYO from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

TOYO cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to several risks and uncertainties, including, among others, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of TOYO, and other risks and uncertainties, including but not limited to those included under the heading “Risk Factors” of the filings of TOYO with the SEC. There may be additional risks that TOYO does not presently know or that TOYO currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of TOYO as of the date of this press release. Subsequent events and developments may cause those views to change. However, while TOYO may update these forward-looking statements in the future, there is no current intention to do so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of TOYO as of any date subsequent to the date of this press release. Except as may be required by law, TOYO does not undertake any duty to update these forward-looking statements.

Contact Information:

For TOYO Co., Ltd.
IR@toyo-solar.com 

Crocker Coulson
Email: crocker.coulson@aummedia.org
Tel: (646) 652-7185

Keypoint Intelligence’s Deborah Hawkins to Speak at RemaxWorld Expo 2025

By
Advertorial Desk
-

FAIRFIELD, N.J., Oct. 14, 2025 /PRNewswire/ — Keypoint Intelligence is pleased to announce that Deborah Hawkins, Group Director of Keypoint Intelligence’s Workplace Group, will be a featured speaker at RemaxWorld Expo 2025, taking place this week October 16–18 at the Zhuhai International Convention & Exhibition Center in Zhuhai, China.

On Friday, October 17, Hawkins will present “How AI Technology is Affecting Market Trends in the Printing Industry.” Her session will explore how artificial intelligence is reshaping the global print and imaging landscape, from automation and predictive analytics to smarter workflows and customer engagement. Drawing from Keypoint Intelligence’s latest research, she will highlight opportunities for manufacturers, dealers, and service providers to use AI as a catalyst for innovation and growth.

“AI has already begun transforming how companies design, produce, and deliver print services,” said Deborah Hawkins. “Understanding these changes and where the market is headed helps businesses stay ahead in an increasingly intelligent and connected world.”

RemaxWorld Expo is the world’s largest annual trade show for the printing, imaging, and office equipment industries, attracting more than 400 exhibitors and 17,000 visitors from around the world. The event serves as a hub for exploring new technologies, connecting with partners, and exchanging ideas that drive the industry forward.

To learn more or to register, please visit: https://www.rtmworld.com/remaxworld/.

About Keypoint Intelligence
For over 60 years, clients in the digital imaging industry have relied on Keypoint Intelligence for independent hands-on testing, lab data, and extensive market research to drive their product and sales success. Keypoint Intelligence has been recognized as the industry’s most trusted resource for unbiased information, analysis, and awards due to decades of analyst experience.

Autoliv and CATARC in Strategic Partnership

By
Advertorial Desk
-

SHANGHAI, Oct. 14, 2025 /PRNewswire/ — Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, and China Automotive Technology and Research Center Co (CATARC), the leading research institution setting standards in China’s automotive sector, have signed a strategic agreement to jointly advance automotive safety standards and innovation in China and beyond.

This partnership brings together Autoliv’s global leadership in automotive safety and CATARC’s comprehensive technical service capabilities to establish an integrated domestic and international service system to identify and enhance safety standards for all vehicles produced in China.

The collaboration will span research and development, testing, certification, and standards alignment-providing technical support for the R&D and global expansion of Chinese automakers.

The collaboration will focus on four key areas:

  • Collaborative Research in Safety Technologies – Advancing next-generation safety systems through quality and innovation.    
  • Testing and Certification Support – Enhancing efficiency and reliability in safety validation processes. 
  • International Business Development – Supporting Chinese OEMs in expanding globally with world-class safety.
  • Public Welfare and Sustainability Initiatives – Promoting safer mobility and sustainable development through joint advocacy and innovation.

“Autoliv has had a strong presence in China for over three decades and this partnership marks a new chapter in our commitment to shaping the future of automotive safety and ensuring high quality in products both in China and globally. Automotive safety products never get a second chance and need to work without any flaws or variations. Together with CATARC, we aim to define the next generation of safety standards and enhance the safety on our roads,” said Fabien Dumont, Executive Vice President & Chief Technology Officer of Autoliv.

CATARC’s strengths in product testing and certification, as well as forward-looking R&D, will be leveraged in this collaboration. The partnership also aims to increase industry-university-research integration and optimize the use of domestic and international R&D resources. By combining regional, industrial, and technological advantages, Autoliv and CATARC will jointly drive innovation and set higher standards for automotive safety.

This agreement builds on years of successful collaboration between the two organizations and reflects a shared vision to make mobility safer for all.

CATARC is an official partner for the World Congress Global NCAP25, which will be held in Shanghai October 15 to 17.

Inquiries: 
Media: media@autoliv.com
Gabriella Etemad, Tel +46 70 612 64 24, Emelie Ericson, Tel +46 70 957 81 35
Investors & Analysts: ir@autoliv.com
Anders Trapp, Tel +46 709 578 171, Henrik Kaar, Tel +46 709 578 114

About Autoliv

Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world, as well as mobility safety solutions, such as commercial vehicles and electrical safety solutions. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2024, our products saved approximately 37,000 lives and reduced around 600,000 injuries.

We have operations in 25 countries, and we drive innovation, research, and development at our 13 technical centers. Our 65,000 employees are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. Sales in 2024 amounted to $10.4 billion. For more information go to www.autoliv.com.

About CATARC

China Automotive Technology and Research Center Co (CATARC) is a central enterprise directly under the supervision of the State-owned Assets Supervision and Administration Commission of the State Council (SASAC). Established in 1985, CATARC is a comprehensive technology enterprise group with extensive influence in the global and domestic automotive industry. CATARC has developed technical service capabilities covering the entire automotive industry chain and product life cycle. Its business spans a wide range of areas including industry services, standards development, policy research, testing and validation and engineering technology R&D.

Safe Harbor Statement

This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/autoliv/r/autoliv-and-catarc-in-strategic-partnership,c4249457

The following files are available for download:

https://mb.cision.com/Main/751/4249457/3721473.pdf

ALV_Press release Autoliv and CATARC in Strategic Partnership

 

1...2,1362,1372,138...6,465Page 2,137 of 6,465